Multiple Sclerosis Trial, Recruiting (NCT05061953)

Multiple Sclerosis Trial, Recruiting NCT05061953 Sponsor: Innodem Neurosciences Condition: Multiple Sclerosis

Printed from Voxsanity (voxsanity.com.au) — NCT05061953 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Multiple Sclerosis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are able to give your own consent to participate in the study
You are 18 years old or older when you join the study
You are able to read in either French or English
You have enough vision (at least 20/100) in at least one eye, even with the help of glasses, contact lenses, or after eye surgery
(For patients with MS only) You have a confirmed MS diagnosis and have not had a noticeable increase in physical disability in the past six months
(For patients with MS only) Your MS is medically stable at the time of your study visit
(For patients with MS only) Your level of physical disability falls within a specific range as measured by a standard MS disability scale (confirm with trial site)

Who may not be able to join:

You have a history of psychiatric conditions that are known to affect movement or eye control
You have another neurological condition that could affect eye movement, such as a misalignment of the eyes, a nerve problem affecting eye movement, or a stroke that has caused vision loss on one side
You have been diagnosed with macular edema or another eye condition that would prevent you from completing the eye movement tests
You have started, changed the dose of, or used inconsistently any medications known to affect eye movement and vision (such as certain sedatives, antipsychotics, or anti-seizure drugs) within the last three months before joining — occasional use for medical procedures may be allowed at the doctor's discretion, but not close to an eye movement assessment
(For healthy volunteers only) You have a history of a significant brain or nervous system condition such as MS, Parkinson's disease, ALS, or dementia
(For MS patients only) You have been diagnosed with Clinically Isolated Syndrome, Radiologically Isolated Syndrome, or Primary Progressive MS
(For MS patients only) You are currently experiencing an MS relapse or have had a relapse within the last three months
(For MS patients only) You have been taking MS disease-modifying therapy for less than three months

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05061953

Sponsor: Innodem Neurosciences

Phase: Not Applicable

Status: Recruiting

Condition: Multiple Sclerosis

More information: https://clinicaltrials.gov/study/NCT05061953

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are able to give your own consent to participate in the study
You are 18 years old or older when you join the study
You are able to read in either French or English
You have enough vision (at least 20/100) in at least one eye, even with the help of glasses, contact lenses, or after eye surgery
(For patients with MS only) You have a confirmed MS diagnosis and have not had a noticeable increase in physical disability in the past six months
(For patients with MS only) Your MS is medically stable at the time of your study visit
(For patients with MS only) Your level of physical disability falls within a specific range as measured by a standard MS disability scale (confirm with trial site)

Who may not be able to join:

You have a history of psychiatric conditions that are known to affect movement or eye control
You have another neurological condition that could affect eye movement, such as a misalignment of the eyes, a nerve problem affecting eye movement, or a stroke that has caused vision loss on one side
You have been diagnosed with macular edema or another eye condition that would prevent you from completing the eye movement tests
You have started, changed the dose of, or used inconsistently any medications known to affect eye movement and vision (such as certain sedatives, antipsychotics, or anti-seizure drugs) within the last three months before joining — occasional use for medical procedures may be allowed at the doctor's discretion, but not close to an eye movement assessment
(For healthy volunteers only) You have a history of a significant brain or nervous system condition such as MS, Parkinson's disease, ALS, or dementia
(For MS patients only) You have been diagnosed with Clinically Isolated Syndrome, Radiologically Isolated Syndrome, or Primary Progressive MS
(For MS patients only) You are currently experiencing an MS relapse or have had a relapse within the last three months
(For MS patients only) You have been taking MS disease-modifying therapy for less than three months

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Innodem Neurosciences

Registry

ClinicalTrials.gov

Start date

18 October 2021

Est. completion

18 October 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Change from Baseline in Symbol Digit Modalities Test (SDMT) score at Month 48

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov